Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Algernon Pharmaceuticals Inc.
C.AGN
Alternate Symbol(s):
AGNPF
Consumer Cyclical
Healthcare
Advertising Agencies
Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N...
-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Company Website
Add To Watchlist
Bullboard (CSE:AGN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(5)
•••
TheBearInTheWoods
X
View Profile
View Bullboard History
Comment by
TheBearInTheWoods
on Mar 28, 2023 11:18pm
RE:A Message To Board Director - Dr. Mark Williams, PhD, MBA
You are still in this dog lmao, ARCH was just given the market cap or AGN in a gov grant for a NEW mechanism of action.
(2)
•••
Whalewatcher1
X
View Profile
View Bullboard History
Post by
Whalewatcher1
on Mar 28, 2023 7:58pm
Trading starting March 29th will be interesting
Shouldnt the stock be trading well below $0.25? if current shareholders can buy the rights offering for $0.25 an get a warrant, won't every current investor be selling at below $0.25? will
...more
Level Up Your Trading with BMO InvestorLine’s Enhanced Features
posted Nov 23, 2024 9:00am by
Bank of Montreal
-
|
Features like Multi-Leg Orders, Options Screener, and Strategy Builder will be particularly exciting for traders. They have been designed to be intuitive and user-friendly, regardless of your experience level. Whether you’re a seasoned pro or just starting out, you’ll find these tools easy to navigate and adapt to your investing style. ...read more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on Mar 28, 2023 7:33pm
RE:Interview with CEO on Upcoming Clinical Trial
Man these bots post up some dumb down stuff. The video attached is from 2 months ago. Is it that hard to see they have NO MONEY to run a Chronic Cough trial or any trial? What money they'll
...more
(127)
•••
SkywalkerofLuke
X
View Profile
View Bullboard History
Post by
SkywalkerofLuke
on Mar 28, 2023 3:58pm
Interview with CEO on Upcoming Clinical Trial
A US survey found that 5% of people (approximately 12.2 million adults) reported experiencing chronic cough in the previous 12 months. The chronic cough market is expected to reach $11.38B by 2029.
...more
(21)
•••
StockHawk1
X
View Profile
View Bullboard History
Post by
StockHawk1
on Mar 27, 2023 6:39pm
AGN DMT-Stroke research video
There are currently very few treatment options for stroke survivors other than blood thinners or surgical intervention. Given the neuro-generative effects of DMT, it could have brain-healing
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Mar 27, 2023 12:37pm
New Press Release - CSE Bulletin: New Listing - Algernon Pharmaceuticals Inc. 27APRIL2023 Rights
Toronto, Ontario--(Newsfile Corp. - Le 27 mars/March 2023) - Algernon Pharmaceuticals Inc. has announced a Rights Offering to eligible shareholders of record at the close of market on March 29, 2023. A holder resident in an Eligible Jurisdiction will be offered one (1) transferable right for each...
read article.
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Mar 27, 2023 2:58am
A Message To Board Director - Dr. Mark Williams, PhD, MBA
t's ok if you let your baby out of it's Play Pen and let it run free. Nobody is going to criticize you for having sidestepped the type of mathematical and methodical missteps that are
...more
(21)
•••
StockHawk1
X
View Profile
View Bullboard History
Post by
StockHawk1
on Mar 24, 2023 7:22pm
AGN's DMT studies
The phara-development company Algernon Pharmaceuticals (AGN.c AGNPF) is helping to pave the way in psychdelic medicine by studying if DMT can help patients with brain injuries. The company is doing
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Mar 24, 2023 2:43am
4 BILLION SHARES In 4+ Years With No End In Sight
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171525796
(21)
•••
StockHawk1
X
View Profile
View Bullboard History
Post by
StockHawk1
on Mar 23, 2023 7:38pm
CEO on DMT study (1st dose completed)
In this interview Algernon Pharmaceuticals (AGN.c AGNPF) CEO shares the news that AGN has completed the first dosing in its Phase 1 clinical study of DMT. The video goes in-depth into AGN's
...more
(16)
•••
waves1
X
View Profile
View Bullboard History
Comment by
waves1
on Mar 23, 2023 4:14pm
RE:Interview with CEO
It's notable that AGN is able to accelerate to a Phase 2 clinical trial of DMT for TBI by using the data from its Phase 1 Study of DMT for Stroke.
(2)
•••
Whalewatcher1
X
View Profile
View Bullboard History
Comment by
Whalewatcher1
on Mar 22, 2023 10:12am
RE:3 Ring Circus Act
Ya, surprised its not trading at $0.25
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Mar 22, 2023 8:38am
3 Ring Circus Act
AGN - AGN Neuro - AGN.RT Why buy/hold 40 cent shares when you can now buy/hold 25 cent shares?
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on Mar 21, 2023 11:02pm
RE:Is this the beginning of the end?
If nothing else...the CEO has a proven track record of Bankrupt companies.
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Mar 21, 2023 10:54pm
The Exercise Of All Warrants Pushes The Split Adjusted...
Outstanding Shares Over 2 Billion
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >